Cost-effectiveness analysis in heart disease, Part II: Preventive therapies (Q40576799)

21 September 2017

1 reference

title

Cost-effectiveness analysis in heart disease, Part II: Preventive therapies (English)

1 reference

21 September 2017

5

1 reference

21 September 2017

Kupersmith J

1

1 reference

21 September 2017

Holmes-Rovner M

series ordinal

2

1 reference

21 September 2017

Hogan A

series ordinal

3

1 reference

21 September 2017

Rovner D

series ordinal

4

1 reference

21 September 2017

1 January 1995

1 reference

Progress in Cardiovascular Diseases

21 September 2017

1 reference

21 September 2017

37

1 reference

21 September 2017

4

1 reference

21 September 2017

243-271

1 reference

Cost-effectiveness analysis in heart disease, Part I: General principles

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost and health implications of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Care of patients with a low probability of acute myocardial infarction. Cost effectiveness of alternatives to coronary-care-unit admission

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost-effectiveness of interventions to prevent or treat coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Free care, cholestyramine, and health policy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Improvement in long-term survival among patients hospitalized with acute myocardial infarction, 1970 to 1980. The Minnesota Heart Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Does free care improve adults' health? Results from a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Serum cholesterol response to changes in the diet: I. Iodine value of dietary fat versus 2S-P

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Community education for cardiovascular health

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Changes in coronary risk factors during comprehensive five-year community programme to control cardiovascular diseases (North Karelia project)

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Contemporary considerations in the treatment of hypertension. Cost, efficacy, and preference. Proceedings of a symposium. September 14, 1986, Washington, D.C.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Variability in the management of hypertension and cost-effectiveness: methodology, community care results and potential cost reductions

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Screening for hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost-effectiveness of educational interventions to improve patient outcomes in blood pressure control

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Measures of clinical efficacy. Cost-effectiveness calculations in the diagnosis and treatment of hypertensive renovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost effectiveness in the detection of renal artery stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The effects of group size on test ordering for hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cooperative study of renovascular hypertension. Demographic analysis of the study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Correlation of Angiography and Natural History in Evaluation of Patients with Renovascular Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Operative Morbidity and Mortality in Renovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Renovascular occlusive disease. Results of operative treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The effects of antihypertensive therapy on the quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The relative impact of health education for low- and high-risk patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The cost-effectiveness of counseling smokers to quit.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost-effectiveness of a smoking cessation program after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The cost-effectiveness of three smoking cessation programs.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Controlled trial of three different antismoking interventions in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Effect of general practitioners' advice against smoking.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Mortality in relation to smoking: 20 years' observations on male British doctors

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

A comparison of psychological and pharmacological treatment in smoking cessation

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cessation of smoking after myocardial infarction. Effects on mortality after 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The Stanford Five-City Project: design and methods

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The economic costs of smoking and benefits of quitting for individual smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Effects of nicotine chewing gum and follow-up appointments in physician-based smoking cessation.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Predictors of smoking cessation after coronary artery bypass graft surgery. Results of a randomized trial with 5-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

A cost-effectiveness analysis of exercise as a health promotion activity

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

An epidemiologic study of the benefits and risks of running

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Physical activity and the incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Stroke Prevention in Atrial Fibrillation Study. Final results

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Canadian atrial fibrillation anticoaguiation (CAFA) study

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Anticoagulation for Noncardiac Procedures in Patients With Prosthetic Heart Valves

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Influence of low-intensity warfarin treatment on patients' perceptions of quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Incidence of systemic embolism before and after mitral valvotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Clinical decisions in the management of the cardiomyopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

The economic value of life: linking theory to practice

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2805%2980009-X

7 January 2021

10.1016/S0033-0620(05)80009-X

Identifiers

DOI

1 reference

21 September 2017

1 reference